APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Study sponsor: Apollomics Inc. · APLM
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2026-03-30Estimated
Enrollment · participants497Estimated
Source updated2025-06-27Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.